MON-565 Patients Thyroidectomized For Thyroid Cancer (without Malabsorption) In Treatment With Oral Liquid L-thyroxine (L-T4) Formulation

We aimed to study the efficacy of levothyroxine (L-T4) liquid formulation in comparison to L-T4 tablets, in patients recently submitted to total thyroidectomy, without malabsorption or drug interference issues. In this study 140 patients were included: 70 received liquid L-T4 formulation; 70 took L-T4 tablets using the same dosage (1.5 mcg/kg/day). The day after surgery, patients received the treatment with L-T4 that was administered 30 min before breakfast. For both the groups of patients thyrotropic hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3), after 6 weeks (1st control), and then after 12 weeks (2nd control), were evaluated. In the liquid L-T4 group TSH values were significantly lower, in comparison to the tablet L-T4 group, in both the first (P < 0.05) and the second control (P < 0.01), while no significant differences were observed for FT4 and FT3. The prevalence of patients in the hypothyroid range (TSH>3.6 mcU/ml) was higher in the L-T4 tablet group with respect to the liquid L-T4 group. In conclusion, these data suggest a better control of TSH levels by liquid L-T4 (versus L-T4 tablets) in patients previously undergone to total thyroidectomy for thyroid cancer without issues of drug interference, malabsorption, or gastric disorders.